Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant

• Status: Completed
• Trial end date: 2012-06-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving bortezomib after an autologous peripheral blood stem cell transplant may stop the growth of any cancer cells that remain after transplant.

PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib in treating patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Barbara Ann Karmanos Cancer Institute
• Collaborator: National Cancer Institute (NCI)
• Treatments: Bortezomib

Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of multiple myeloma

• Must have completed high-dose melphalan and autologous peripheral blood stem cell transplantation

• Transplant must have been completed 30-120 days ago

• Must not be receiving maintenance therapy

• Patients must have received 200 mg/m² of melphalan intravenously as a conditioning regimen (no dose reduction allowed)

• No evidence of amyloidosis

• No available donor

PATIENT CHARACTERISTICS:

• ECOG performance status (PS) 0-2 or Karnofsky PS 60-100%

• Absolute neutrophil count > 1,500/mm^3

• Platelet count > 75,000/mm^3

• Bilirubin ≤ 1.5 times upper limit of normal

• Transaminase ≤ 3 times upper limit of normal

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• Must have a negative HIV test

• No baseline neurological disease > grade I

• No cranial nerve palsy

• No demonstrated resistance to bortezomib

• No history of allergic reactions attributed to bortezomib, boron, or mannitol

• No cardiac arrhythmia

• No unstable angina pectoris

• No symptomatic congestive heart failure

• No ongoing or active infection

• No other uncontrolled illness

• No psychiatric illness or social situations that would limit compliance with study requirements

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• No other concurrent anticancer therapies or agents

• No other concurrent investigational agents

• Not receiving maintenance therapy after prior stem cell transplantation on another clinical trial